Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?

J Cyst Fibros. 2024 Mar;23(2):366-367. doi: 10.1016/j.jcf.2023.10.008. Epub 2023 Oct 13.

Author

V Terlizzi¹

Affiliation

¹ Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy. Electronic address: vito.terlizzi@meyer.it.

PMID: 37838487
DOI: 10.1016/j.jcf.2023.10.008

No abstract available

Publication types

Letter

MeSH terms

Aminophenols* / therapeutic use
Benzodioxoles* / therapeutic use
Child
Chloride Channel Agonists / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Drug Combinations
Humans
Indoles* / therapeutic use
Pyrazoles* / therapeutic use
Pyridines* / therapeutic use
Pyrroles / therapeutic use
Pyrrolidines
Quinolines / therapeutic use
Quinolones* / therapeutic use

Substances

elexacaftor
tezacaftor
ivacaftor
elexacaftor, ivacaftor, tezacaftor drug combination